Highest-materiality recent filing
Fulcrum to merge with Slate Medicines; Slate holders to own ~95% of combined company
Merger values Slate at $350M, Fulcrum at $31.3M; post-close ownership: Slate holders ~55.9%, investors ~39.1%, Fulcrum ~5.0%.
Fulcrum approves retention bonuses for CEO, CLO, CFO; accounting officer departs after restructuring
CEO Alex Sapir receives $370,040 retention bonus; CLO Curtis Oltmans $195,480; CFO Alan Musso $195,200.
Fulcrum cuts workforce 85% after SCD drug failure; hires Leerink for strategic review
Workforce reduced from 57 to 9 employees (~85% cut) after discontinuing pociredir for sickle cell disease.
Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review
Discontinued pociredir for sickle cell disease after FDA feedback; no viable regulatory path forward.
CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
Fulcrum Therapeutics Q4/FY2025: positive pociredir Phase 1b HbF data; net loss widens to $74.9M
Positive 12-week pociredir Phase 1b results: mean absolute HbF increased 12.2% (7.1% to 19.3%); improvements in hemolysis, anemia, and VOC trends.
Fulcrum reports ~$352.3M cash as of Dec 31, 2025; updates presentation for JPM conference
Preliminary unaudited cash, cash equivalents and marketable securities of $352.3M as of December 31, 2025.
Fulcrum Therapeutics prices $175M upsized public offering of common stock and pre-funded warrants
Priced underwritten offering of 11,851,853 shares at $13.50/share and pre-funded warrants for 1,111,193 shares at $13.499 each.
Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.
Fulcrum Therapeutics Q3 loss $19.6M; pociredir 20mg cohort enrolled, data due year-end
Cash, equivalents and marketable securities $200.6M; cash runway into 2028.
Fulcrum Q2 net loss $17.3M; pociredir Phase 1b shows HbF increase 8.6% in SCD
Q2 2025 net loss $17.3M vs net income $55.4M in Q2 2024; cash $214.1M, runway into 2028.
Fulcrum Q1 net loss $17.7M; pociredir 12mg cohort enrolled, 20mg cohort initiated
Net loss of $17.7M for Q1 2025 vs $26.9M in Q1 2024; cash $226.6M at March 31, 2025.
MyoKardia terminates Fulcrum collaboration; Fulcrum loses future milestones and royalties
MyoKardia (BMS unit) terminated the collaboration agreement for convenience; effective June 26, 2025.
Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027
Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones
Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
Fulcrum Therapeutics Q3 net loss $21.7M, cash $257.2M; losmapimod halted, PIONEER trial ongoing
Net loss $21.7M in Q3 2024 vs $24.0M loss in Q3 2023; R&D expenses down to $14.6M from $18.2M.
Fulcrum Therapeutics reduces workforce from 80 to 51, expects $10M annual savings
Workforce reduction of 29 employees (36%) to focus on pociredir, DBA, and early discovery; suspends losmapimod.
Fulcrum Therapeutics Phase 3 losmapimod trial fails; program suspended
REACH trial missed primary endpoint: RSA change p=0.75 vs placebo at week 48.
RA Capital exchanged 8,500,000 shares for a pre-funded warrant for 8,500,000 shares at $0.001 exercise price, no expiration.
Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024
Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
Fulcrum signs $80M upfront Sanofi deal for losmapimod ex-U.S.; Q1 net loss $26.9M
Sanofi pays $80M upfront; Fulcrum eligible for up to $975M in milestones and tiered low-teens to mid-twenties royalties on ex-U.S. sales.
Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024
Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).
Completed enrollment in Phase 3 REACH trial of losmapimod for FSHD; topline data expected Q4 2024.
Fulcrum Therapeutics announces FDA lifts clinical hold on FTX-6058 IND for sickle cell disease
FDA lifted clinical hold on Fulcrum's IND for FTX-6058 on August 22, 2023.
Fulcrum Therapeutics reports Q2 net loss $23.8M, closes FSHD trial screening, appoints CFO
Net loss of $23.8M in Q2 2023, improved from $34.1M in Q2 2022; cash $278.2M.
Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties
Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.
Alex Sapir appointed CEO/President effective July 1, 2023; he will serve as special advisor until then.
Fulcrum Therapeutics CFO Esther Rajavelu resigns effective April 21, 2023
CFO Esther Rajavelu resigns effective April 21, 2023 to pursue another opportunity.
FDA places FTX-6058 on clinical hold; Fulcrum reports Q4/FY2022 results
FDA placed full clinical hold on FTX-6058 IND for sickle cell disease; enrollment paused and dosing suspended.
Offered 9,615,384 shares at $13.00 per share; gross proceeds of $125 million.
Fulcrum announces $100M stock offering and preliminary $202.9M cash position
Preliminary cash, cash equivalents, and marketable securities of ~$202.9M as of Dec 31, 2022.
CEO transition and positive FTX-6058 Phase 1b data; cash runway into late 2024
CEO Bryan Stuart departs; Robert Gould, former CEO/board member, appointed interim CEO effective Jan 3, 2023.
Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial
Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.
Fulcrum Therapeutics announces $75M public offering of common stock at $7.82/share
9,590,792 shares offered at $7.82/share; gross proceeds $75 million.
Fulcrum Therapeutics Q2 net loss $34.1M; cuts 18 jobs, saves $40-50M, cash into mid-2024
Net loss $34.1M ($0.65 per share) vs $19.6M in Q2 2021; cash $169M as of June 30.
Fulcrum reports positive Phase 1b data for FTX-6058 in sickle cell disease; HbF up 6.3%
FTX-6058 achieved up to 6.3% increase in fetal hemoglobin (HbF) over baseline in Phase 1b trial.
On June 10, 2026, Fulcrum and Greg Tourangeau, Fulcrum’s Vice President, Finance and principal accounting officer, mutually agreed that Mr. Tourangeau will depart from his position at Fulcrum on a date to be agreed between Mr. Tourangeau and Fulcrum.
On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.
On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.
elected Colin Hill as a member of the Board, effective June 17, 2024
On September 28, 2023, in connection with a decision to streamline certain functions within the company, Fulcrum Therapeutics, Inc., or Fulcrum, notified Mel Hayes, Fulcrum’s current chief operating officer (and principal operating officer) that it was eliminating his position effective October 2, 2023, following which, Fulcrum does not have a principal operating officer. Mr. Hayes agreed to remain with Fulcrum as its Executive Vice President, Patient Experience, and in connection therewith, entered into an amended and restated employment agreement reflecting his new role and title at Fulcrum.
On August 2, 2023, Fulcrum’s board of directors, or the Board, appointed Alan A. Musso as Fulcrum’s chief financial officer and treasurer, effective August 7, 2023.
On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
On May 11, 2023, in recognition of the duties he is performing and the vacancy in the chief financial officer position, Fulcrum’s board of directors, or the Board, appointed Robert E. Gould, current interim president and chief executive officer, as principal financial officer, with immediate effect.
Mr. Sapir will succeed Dr. Gould as principal executive officer and as principal financial officer effective July 1, 2023. Dr. Gould will remain on the Board as a class III director.
On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum’s president and chief executive officer, and as a class II director, effective July 1, 2023.
On March 31, 2023, Esther Rajavelu notified Fulcrum Therapeutics, Inc., or Fulcrum, of her intent to resign as chief financial officer and treasurer (and as principal financial officer), effective April 21, 2023, to pursue another opportunity.
On January 2, 2023, Bryan Stuart and Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed that he would transition from his role as president, chief executive officer and as Class II director
Max materiality 1.00 · Median 0.65 · Most common event other_material